Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2004-08-23
2008-08-05
Prouty, Rebecca E. (Department: 1652)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C435S069100
Reexamination Certificate
active
07407935
ABSTRACT:
Disclosed herein are polypeptides and variants thereof comprising a polypeptide sequence having substantial identity to ricin A chain (RTA) that lack detectable N-glycosidase-rRNA activity or exhibit reduced N-glycosidase-rRNA activity as compared to controls and methods of making and using thereof. The polypeptides and variants have a greater solubility in aqueous solutions of physiological pH and ionic strength than RTA and also retain the integrity of the neutralizing immunological epitope of wild type RTA. Also disclosed are immunogenic compositions that may be used to immunize a subject against ricin intoxication. Methods of immunizing against, treating, and preventing ricin intoxication are disclosed.
REFERENCES:
patent: 4080457 (1978-03-01), Harrison et al.
patent: 4689401 (1987-08-01), Ferris
patent: 4962188 (1990-10-01), Frankel
patent: 5376546 (1994-12-01), Bernhard et al.
patent: 5416202 (1995-05-01), Bernhard et al.
patent: 5453271 (1995-09-01), Lemley et al.
patent: 5547867 (1996-08-01), Kara et al.
patent: 5621083 (1997-04-01), Better et al.
patent: 5622838 (1997-04-01), Lord et al.
patent: 5626844 (1997-05-01), Lemley et al.
patent: 5646026 (1997-07-01), Walsh et al.
patent: 5744580 (1998-04-01), Better et al.
patent: 5756699 (1998-05-01), Better et al.
patent: 5837491 (1998-11-01), Better et al.
patent: 5877305 (1999-03-01), Huston et al.
patent: 6060066 (2000-05-01), Lemley, Jr. et al.
patent: 6084073 (2000-07-01), Piatak, Jr.
patent: 6333303 (2001-12-01), Borgford
patent: 6531125 (2003-03-01), Borgford
patent: WO 88/09344 (1988-12-01), None
patent: WO 00/53215 (2000-09-01), None
Roberts et al. (GenBank Acc No. P06750, Jan. 1, 1988).
Wood et al. (GenBank Acc No. P28590, Dec. 1, 1992).
Aboud-Pirak, E, et al. (1993) “Identification of Neutralizing Epitope on a Chain and Application”, Medical Defense Bioscience Review, Proceedings (5):1431-1440.
Afrin, LB, et al (1994) “Expression of Oligohistidine-Tagged Ricin B. Chain inSpodoptera frugiperd” Bioconjugate Chem. 5(6):539-546.
Appukuttan, PS, et al (1979) “Separation of Polypeptide Chains of Ricin and the Interaction of the A Chain With Cibacron Blue F3GA” Biochimica et Biophysica Acta, 580:10-14.
Argent, RH, et al. (1995) “Purification of Recombinant Ricin A Chain after Reassociation with Ricin B Chain” Analytical Biochemistry (224):459-460.
Blakey, DC, et al. (1987) “Effect of Chemical Deglycosylation of Ricin A Chain on the in Vivo Fate and Cytotoxic Activity of an Immunotoxin Composed of Ricin A Chain and Anti-Thy 1.1 Antibody”, Cancer Research (47):947-952.
Baluna, R, et al. (1999) “Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome”, Proc. Natl. Acad. Sci. (96):3957-3963.
Bradley, JL, et al. (1989) “Site-directed mutagenesis at amino terminus of recombinant ricin A chain” Int. J. Peptide Protein Res. (34):2-5.
Brigotti, M, et al. (1998) “A rapid and sensitive method to measure the enzymatic activity of ribosome-inactivating proteins” Nucleic Acids Research, (26):18.
“Chemical Warfare Agents, and Related Chemical Problems, Parts I-II”, Ricin, Chapter 12, Summary Technical Report of Div. 9, NDRA, vol. 1 (1946).
Byers, V, et al. (1993) “Suppression of Antibody Responses to Ricin A Chain (RTA) by Monoclonal Anti-RTA Antibodies” Journal of Clinical Immunology, (13):6.
Chang, MS, et al. (1987) “Cloning and expression of recombinant, functional ricin B chain” Proc. Natl. Acad. Sci, (84):5640-5644.
Chanh, TC, et al. (1993) “Monoclonal Antibody Prophylaxis Against the In Vivo Toxicity of Ricin in Mice” Immunological Investigations 22(1):63-72.
Colombatti, M, et al. (1986) “Monoclonal Antibodies Against Ricin: Effects on Toxin Function” Hybridoma 5(1): 9-19.
Day, PJ, et al. (1996) “Structure and Activity of an Active Site Substitution of Ricin A Chain” Biochemistry (35): 11098-11103.
Despeyroux, D, et al. (2000) “Characterization of Ricin Heterogeneity by Electrospray Mass Spectrometry, Capillary Electrophoresis, and Resonant Mirror”, Analytical Biochemistry (279):23-36.
Emmanuel, F, et al. (1988) “Separation of Ricin A- and B-Chains after Dithiothreitol Reduction” Analytical Biochemistry (173):134-141.
Ferrini, JB, et al. (1995) “Expression of functional ricin B chain using the baculovirus system” Eur. J. Biochem. (233):772-777.
Foxwell, BM, et al. (1987) “The preparation of deglycosylated ricin by recombination of glycosidase-treated A- and B-chains: effects of deglycosylation on toxicity and in vivo distribution” Biochimica et Biophysica Acta (923):59-65.
Foxwell, BMJ, et al. (1985) “The removal of carbohydrates from ricin with endoglycosidases H, F and D and α-mannosidase”, Biochimica et Biophysica Acta (840):193-203.
Foxwell, BMJ, et al. (1985) “The Use of Anti-ricin Antibodies to Protect Mice Intoxicated with Ricin” Toxicology, (34):79-88.
Frankel, A, et al. (1994) “Expression of ricin B chain inSpodoptera frugiperda” Biochem. J. (303):787-794.
Frankel, A, et al. (1989) “Selection and Characterization of Ricin Toxin A-Chain Mutations inSaccharomyces cerevisiae” Molecular and Cellular Biology, 9(2):415-420.
Franz, DR, et al. “Ricin Toxin”Medical Aspects of Chemical & Biologcal Warfare 631-642.
Frénoy, JP (1986) “Effect of physical environment on the conformation of ricin” Biochem. J. (240):221-226.
Frénoy, JP et al. (1986) “Structure and stability ofRicinus communishaemagglutinin” Biochem. J. (240)227-231.
Frigerio, L, et al. (2001) “The Internal Propeptide of the Ricin Precursor Carries a Sequence-Specific Determinant for Vacuolar Sorting”Plant Physiology(126):167-175.
Fulton, R.J., et al. (1986) “Purification of Ricin A1, A2, and B Chains and Characterization of Their Toxicity” The Journal of Biological Chemistry 261 (12):5314-5319.
Furukawa-Stoffer, TL, et al. (1999) “A Novel Biological-Based Assay for the Screening of Neutralizing Antibodies to Ricin” Hybridoma 18(6):505-510.
Griffiths, GD, et al. (1999) “Comparison of the quality of protection elicited by toxoid and peptide liposomal vaccine formulations against ricin as assessed by markers of inflammation” Vaccine (17):2562-2568.
Griffiths, GD, et al. (1995) “Protection against inhalation toxicity of ricin and abrin by immunisation” Human & Experimental Toxicology (14):155-164.
Griffiths, GD, et al. (1997) “Liposomally-encapsulated ricin toxoid vaccine delivered intratracheally elicits a good immune response and protects against a lethal plumonary dose of ricin toxin” Vaccine 15(17/18):1933-1939.
Griffiths, GD, et al. “The inhalation toxicology of the castor bean toxin, ricin, and protection by vaccination” Journal of Defense Science 1(2):227-235.
Hale, ML (2001) “Microtiter-Based Assay for Evaluating the Biological Activity of Ribosome-Inactivating Proteins” Pharmacology & Toxicology (88):255-260.
Hewetson, JF, et al. (1993) “Protection of mice from inhaled ricin by vaccination with ricin or by passive treatment with heterologous antibody” Vaccine 11(7):743-746.
Hussain, K, et al. (1989) “Expression of ricin B chain inEscherichia coli” FEBS Letters 244(2):383-387.
Katzin, BJ, et al. (1991) “Structure of Ricin A-Chain at 2.5 Å”Proteins: Structure, Function, and Genetics (10):251-259.
Kim, Y, et al. (1992) “Analysis of several key active site residues of ricin A chain by mutagenesis and X-ray crystallography” Protein Engineering 5(8):775-779.
Kim, Y, et al. (1992) “Structure of a Ricin Mutant Showing Rescue of Activity by a Noncatalytic Residue” Biochemistry (31):3294-3296.
Kurinov, IV, et al. (1
Byrne Michael P.
Millard Charles B.
Olson Mark A.
Wannemacher Robert W.
Arwine Elizabeth
Kosson Rosanne
Prouty Rebecca E.
The United States of America as represented by the Secretary of
LandOfFree
Ricin toxin A-chain fragment for use as a vaccine does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ricin toxin A-chain fragment for use as a vaccine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ricin toxin A-chain fragment for use as a vaccine will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4005235